98 related articles for article (PubMed ID: 21993737)
21. PDUFA reauthorization--drug safety's golden moment of opportunity?
Hennessy S; Strom BL
N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
[No Abstract] [Full Text] [Related]
22. Conflict of interest in industry-sponsored drug development.
Emanuel EJ
Clin Adv Hematol Oncol; 2007 Apr; 5(4):265-7. PubMed ID: 17607285
[No Abstract] [Full Text] [Related]
23. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
24. [Conflicts of interest for Swiss physicians].
Hurst S
Rev Med Suisse; 2011 Jun; 7(301):1434. PubMed ID: 21815502
[No Abstract] [Full Text] [Related]
25. Drug scandal exposes French regulators to public ire.
Casassus B
Nat Med; 2011 Feb; 17(2):144. PubMed ID: 21297596
[No Abstract] [Full Text] [Related]
26. Benfluorex: analysis of a drug-related public health crisis.
Menard J
Diabetes Metab; 2011 Jun; 37(3):169-75. PubMed ID: 21612964
[No Abstract] [Full Text] [Related]
27. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
28. Lessons from Eprex for biogeneric firms.
Louët S
Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
[No Abstract] [Full Text] [Related]
29. California campuses resist industry restrictions.
Check E
Nature; 2007 Jul; 448(7152):394-5. PubMed ID: 17653150
[No Abstract] [Full Text] [Related]
30. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
31. Regulators need to regulate. For health and safety issues, the nation needs watchdogs to be on guard.
May D
Mod Healthc; 2010 Mar; 40(9):16. PubMed ID: 20344831
[No Abstract] [Full Text] [Related]
32. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Karst KR
Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
[No Abstract] [Full Text] [Related]
33. [Expectations and obligations].
Haug C
Tidsskr Nor Laegeforen; 2002 Jun; 122(17):1637. PubMed ID: 12555600
[No Abstract] [Full Text] [Related]
34. FDA revamps committee conflict-of-interest rules.
Finkelstein JB
J Natl Cancer Inst; 2006 Oct; 98(19):1354-5. PubMed ID: 17018777
[No Abstract] [Full Text] [Related]
35. US proposes more stringent conflict-of-interest rules.
Kondro W
CMAJ; 2007 May; 176(11):1571-2. PubMed ID: 17515579
[No Abstract] [Full Text] [Related]
36. Ensuring the safety of genotech drugs through implied warranty theory.
Serra WM
Am J Law Med; 1997; 23(2-3):363-81. PubMed ID: 9262761
[No Abstract] [Full Text] [Related]
37. [Increased commercial financing of national Medical Product Agencies within the EU].
Ramel B
Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381
[No Abstract] [Full Text] [Related]
38. Must an interest be a conflict?
Lyles A
Clin Ther; 2005 Mar; 27(3):344-5. PubMed ID: 15878388
[No Abstract] [Full Text] [Related]
39. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
DerGurahian J
Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
[No Abstract] [Full Text] [Related]
40. California dreaming.
Nature; 2007 Jul; 448(7152):388. PubMed ID: 17653147
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
